Sunday, May 14, 2023 3:17:11 AM
Congrats to longs. Monday should be a good day. Anyone following Capricor - CAPR
CEO said CAPR drug helps cardiac election fraction and helps upper limb function in DMD. She says combination with Sarepta’s drug could be better than either alone. Maybe Sarepta should by Capricor?
CEO said CAPR drug helps cardiac election fraction and helps upper limb function in DMD. She says combination with Sarepta’s drug could be better than either alone. Maybe Sarepta should by Capricor?
Bullish
Recent SRPT News
- Sarepta Therapeutics to Participate in Upcoming Investor Conferences • Business Wire • 06/01/2026 08:30:00 PM
- Breakthrough Pipelines Ignite Investor Excitement: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine • GlobeNewswire Inc. • 05/27/2026 12:45:00 PM
- Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference • Business Wire • 05/13/2026 08:30:00 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/13/2026 08:22:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:10:17 PM
- Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments • Business Wire • 05/06/2026 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 08:01:49 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:11:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:10:20 PM
- Sarepta Therapeutics to Announce First Quarter 2026 Financial Results • Business Wire • 04/22/2026 12:30:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • InvestorsHub NewsWire • 04/20/2026 01:00:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/31/2026 08:05:00 PM
- Sarepta shares jump after early clinical data from siRNA programs • IH Market News • 03/25/2026 03:31:46 PM
- Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 • Business Wire • 03/25/2026 12:05:00 PM
- Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 • Business Wire • 03/24/2026 08:05:00 PM
- Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® • Business Wire • 03/19/2026 12:30:00 PM
- Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne • Business Wire • 03/16/2026 12:33:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2026 12:09:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2026 12:05:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2026 12:03:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2026 12:01:03 AM
